Inhibikase Therapeutics
Balance Sheet

Last updated:

The balance sheet is a financial statement presenting the value of assets, liabilities and equity of a company. How has Inhibikase Therapeutics's balance sheet done over the years? Its assets were worth $14,506,647 last year, which is less than in the previous period. 24% of Inhibikase Therapeutics’s total assets is currently financed by debt. Its liabilities reached the amount of $3,528,725, which means an decrease by -10% compared compared to last year.

Debt to Assets

Inhibikase Therapeutics, Inc. (NASDAQ:IKT): Debt to assets
2017 285167 1.72M 605.32%
2018 2846446 3.62M 127.33%
2019 38254 4.52M 11837.38%
2020 14782706 4.99M 33.81%
2021 42469999 4.05M 9.55%
2022 24936297 3.90M 15.64%
2023 14506647 3.52M 24.32%

IKT Balance Sheet (2017 – 2023)

2023 2022 2021 2020 2019 2018 2017
Assets
Current assets:
Cash and cash equivalents
9.16M7.18M40.75M13.95M18.45K379.55K16.66K
Short term investments
4.08M15.86M00000
Net receivables
039.88K110.14K00472.94K180.78K
Inventory
01.11M107K0000
Other current assets
958.99K163.45K1.50M54.83K16.92K399.08K625
Total current assets
14.21M24.37M42.46M14.78M35.38K1.25M198.07K
Non-current assets:
Property, Plant and Equipment
295.59K565.17K00000
Goodwill
0000000
Intangible assets
0000000
Long term investments
0-15.84M000087.09K
Other non-current assets
015.84M002.87K00
Total non-current assets
295.59K565.17K002.87K1.59M87.09K
Total assets
14.50M24.93M42.46M14.78M38.25K2.84M285.16K
Liabilities
Current liabilities:
Accounts payable
Deferred revenue
0002.32M1.42M262.36K5.64K
Short term debt
531.87K145.83K248.91K42.53K98.41K233.72K454.32K
Total current liabilities
3.43M3.69M4.05M4.72M4.25M3.62M1.72M
Non-current liabilities:
Long term debt
90.12K205.45K0276.46K275.37K00
Deferred tax
0000000
Other non-current liabilities
002.71M-276.46K-275.37K1.45M0
Total non-current liabilities
90.12K205.45K2.71M276.46K275.37K1.45M0
Total liabilities
3.52M3.90M4.05M4.99M4.52M3.62M1.72M
Data sourceData sourceData sourceData source